Study Assesses Epidemiology of Carbapenem-resistant Enterobacteriaceae
the ONA take:
Most carbapenem-resistant enterobacteriacecae (CRE) cases in the United States are associated with a high prevalence of prior hospitalizations or indwelling devices and discharge to long-term care settings, a study published in JAMA has shown.
Because CRE cases have been increasingly reported worldwide as a cause of infection with high-mortality rates, researchers sought to determine the population-based CRE incidence in seven US geographical areas.
For the study, researchers analyzed case records from persons living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon.
Results showed that the incidence of CRE was 2.93 per 100,000 people. Researchers also found that the majority of CRE cases were in women.
CRE cases were significantly higher than predicted for Georgia, Maryland, and New York, while Colorado, New Mexico, and Oregon had significantly fewer cases than predicted.
The study demonstrated that most CRE cases occurred in patients with prior hospitalizations or indwelling devices, and the majority of admitted cases results in discharge to a long-term care setting.
The carbapenem antibiotic class includes imipenem, meropenem, doripenem, and ertapenem. Extended-spectrum cephalosporin-resistant enterobacteriaceae are typically susceptible to carbapenems except ertapenem.
Most carbapenem-resistant enterobacteriacecae (CRE) cases associated with a high prevalence of prior hospitalizations.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|